Detemir insulin for the treatment of diabetes mellitus in dogs

• Autores: Federico Fracassi, Claudia E. Reusch, Sara Corradini, Michaela Hafner, Felicitas S. Boretti, Nadia S. Sieber Ruckstuhl
• Localización: JAVMA: Journal of the American Veterinary Medical Association, ISSN-e 0003-1488, Vol. 247, Nº. 1, 2015, págs. 73-78
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Objective—To investigate the effects of insulin detemir in dogs with diabetes mellitus.

    Design—Prospective, uncontrolled clinical trial.

    Animals—10 client-owned dogs with naturally occurring diabetes mellitus.

    Procedures—Dogs were treated with insulin detemir SC every 12 hours for 6 months. Follow-up evaluations were done at 1, 2, 4, 12, and 24 weeks and included evaluation of clinical signs and measurement of blood glucose concentration curves and serum fructosamine concentrations.

    Results—Insulin detemir administration resulted in a significant decrease in blood glucose and serum fructosamine concentrations at 6 months, compared with pretreatment values. Median insulin dosage at the end of the study was 0.12 U/kg (0.055 U/lb; range, 0.05 to 0.34 U/kg [0.023 to 0.155 U/lb], SC, q 12 h). Hypoglycemia was identified in 22% (10/45) of the blood glucose concentration curves, and 6 episodes of clinical hypoglycemia in 4 dogs were recorded. A subjective improvement in clinical signs was observed in all dogs during the 6-month study period. On the basis of clinical signs and blood glucose concentration curves, efficacy of insulin detemir at the end of the study was considered good in 5 dogs, moderate in 3, and poor in 2.

    Conclusions and Clinical Relevance—Results suggested that SC injection of insulin detemir every 12 hours may be a viable treatment for diabetes mellitus in dogs. Insulin detemir dosages were lower than reported dosages of other insulin types needed to maintain glycemic control, suggesting that insulin detemir should be used with caution, especially in small dogs.